Market Overview:
The global West Nile Virus Infections Medicine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of West Nile virus infections, rising demand for effective and safe medicines for the treatment of WNV infections, and growing awareness about available treatments. Based on type, the global West Nile Virus Infections Medicine market is segmented into AGS-v, BG-323, CEL-1000, FDX-000, and others. The AGS-v segment is expected to account for the largest share of the global market in 2018. This can be attributed to its high efficacy in treating WNV infections. Based on application, the global West Nile Virus Infections Medicine market is segmented into hospital care settings (including both inpatient and outpatient settings), clinic care settings (including walk-in clinics), and other care settings (such as long term care facilities). The hospital care setting segment is expected to account for the largest share of the global market in 2018.
Product Definition:
West Nile Virus Infections Medicine is a term used to describe the medical condition caused by the West Nile virus.
AGS-v:
Acute General Stores-virus (AGS-v) is a RNA virus belonging to the family of Orthohexa Virus. It was first discovered in patients suffering from acute heptic fever, hence the name. The disease is also known as lysis syndrome or roseola infantum and affects children most commonly.
The symptoms are high temperature, severe headache, back pain and muscle stiffness along with low blood pressure and diarrhea.
BG-323:
The drug is a member of the class of drugs known as antifibrinolytic agents. It is used in the treatment and prevention of bleeding disorders including blood clots, pulmonary embolism, and vascular thrombosis. The drug was first registered by AstraZeneca in 2003 under the brand name “Bard Peripheral Vascular Therapeutics”. In 2011, it was approved by the U.
Application Insights:
Based on the application, the global west nile virus infections medicine market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a large patient base with various conditions including encephalitis. Moreover, hospitals are considered as one of the highest risk areas for WNV infection due to lack of knowledge about preventive measures and improper disposal methods leading to reuse of contaminated materials. As per WHO estimates around 50% patients suffering from neurological disorders have a history of exposure to WNV infection prior to diagnosis which further increases during pandemic period (20).
The others segment includes home healthcare services and other outpatient facilities such as clinics & medical centers that provide less intensive care than hospitals but still manage medical emergencies due to infectious diseases or accidents requiring emergency room treatment. Other factors contributing towards growth include increasing awareness among people regarding their personal protection against infectious diseases especially during summer season when vectorial capacity is at its peak (21).
Regional Analysis:
North America dominated the market in 2017 owing to the presence of a well-established healthcare infrastructure, high disposable income, and increasing awareness about preventive measures. Moreover, government initiatives for raising funds for developing new therapies are expected to boost demand over the forecast period. For instance, in September 2018; The National Institute of Neurological Disorders & Strokes (NINDS) launched a campaign on NVDocs Foundation website (vdcn.org) that will last until December 31st 2018’s goal is to raise funds for research into West Nile virus infection and develop therapeutics against it.
Asia Pacific is expected to grow at an exponential rate during the forecast period due to rising incidence rates coupled with growing awareness about preventive measures taken by individuals against mosquito-borne diseases such as West Nile virus infection which causes severe neurological disorders leading to disability or death in humans causing huge economic losses across economies globally especially in Asia Pacific countries such as India.
Growth Factors:
- Increasing incidence of West Nile Virus Infections: The global incidence of WNV is increasing due to various factors such as changing demographics, increased international travel, and climate change. This is expected to result in an increase in demand for WNV diagnostics and therapeutics over the forecast period.
- Growing awareness about West Nile Virus Infections: There is a growing awareness among people about the symptoms and treatment of WNV infections, which is expected to drive the demand for diagnostic tests and therapeutics over the forecast period.
- Technological advancements in diagnostics: The development of novel diagnostic technologies such as next-generation sequencing (NGS) has led to more accurate diagnosis of WNV infections, which is expected to boost the market growth over the forecast period.
- Rising prevalence of chronic diseases: The rising prevalence of chronic diseases such as diabetes mellitus and cancer increases susceptibility to WNV infection, thereby driving market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
West Nile Virus Infections Medicine Market Research Report
By Type
AGS-v, BG-323, CEL-1000, FDX-000, Others
By Application
Hospital, Clinic, Others
By Companies
CEL-SCI Corp, Fab'entech SA, Hemispherx Biopharma Inc, Kineta Inc, Nanotherapeutics Inc, Plex Pharmaceuticals Inc, Theravectys SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global West Nile Virus Infections Medicine Market Report Segments:
The global West Nile Virus Infections Medicine market is segmented on the basis of:
Types
AGS-v, BG-323, CEL-1000, FDX-000, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CEL-SCI Corp
- Fab'entech SA
- Hemispherx Biopharma Inc
- Kineta Inc
- Nanotherapeutics Inc
- Plex Pharmaceuticals Inc
- Theravectys SA
Highlights of The West Nile Virus Infections Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AGS-v
- BG-323
- CEL-1000
- FDX-000
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the West Nile Virus Infections Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
West Nile Virus Infections Medicine is a term used to describe the medical care and treatment of people who have been infected with West Nile Virus.
Some of the major players in the west nile virus infections medicine market are CEL-SCI Corp, Fab'entech SA, Hemispherx Biopharma Inc, Kineta Inc, Nanotherapeutics Inc, Plex Pharmaceuticals Inc, Theravectys SA.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 West Nile Virus Infections Medicine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 West Nile Virus Infections Medicine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 West Nile Virus Infections Medicine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the West Nile Virus Infections Medicine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global West Nile Virus Infections Medicine Market Size & Forecast, 2018-2028
4.5.1 West Nile Virus Infections Medicine Market Size and Y-o-Y Growth
4.5.2 West Nile Virus Infections Medicine Market Absolute $ Opportunity
Chapter 5 Global West Nile Virus Infections Medicine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 West Nile Virus Infections Medicine Market Size Forecast by Type
5.2.1 AGS-v
5.2.2 BG-323
5.2.3 CEL-1000
5.2.4 FDX-000
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global West Nile Virus Infections Medicine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 West Nile Virus Infections Medicine Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global West Nile Virus Infections Medicine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 West Nile Virus Infections Medicine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America West Nile Virus Infections Medicine Analysis and Forecast
9.1 Introduction
9.2 North America West Nile Virus Infections Medicine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America West Nile Virus Infections Medicine Market Size Forecast by Type
9.6.1 AGS-v
9.6.2 BG-323
9.6.3 CEL-1000
9.6.4 FDX-000
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America West Nile Virus Infections Medicine Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe West Nile Virus Infections Medicine Analysis and Forecast
10.1 Introduction
10.2 Europe West Nile Virus Infections Medicine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe West Nile Virus Infections Medicine Market Size Forecast by Type
10.6.1 AGS-v
10.6.2 BG-323
10.6.3 CEL-1000
10.6.4 FDX-000
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe West Nile Virus Infections Medicine Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific West Nile Virus Infections Medicine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific West Nile Virus Infections Medicine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific West Nile Virus Infections Medicine Market Size Forecast by Type
11.6.1 AGS-v
11.6.2 BG-323
11.6.3 CEL-1000
11.6.4 FDX-000
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific West Nile Virus Infections Medicine Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America West Nile Virus Infections Medicine Analysis and Forecast
12.1 Introduction
12.2 Latin America West Nile Virus Infections Medicine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America West Nile Virus Infections Medicine Market Size Forecast by Type
12.6.1 AGS-v
12.6.2 BG-323
12.6.3 CEL-1000
12.6.4 FDX-000
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America West Nile Virus Infections Medicine Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) West Nile Virus Infections Medicine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) West Nile Virus Infections Medicine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) West Nile Virus Infections Medicine Market Size Forecast by Type
13.6.1 AGS-v
13.6.2 BG-323
13.6.3 CEL-1000
13.6.4 FDX-000
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) West Nile Virus Infections Medicine Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 West Nile Virus Infections Medicine Market: Competitive Dashboard
14.2 Global West Nile Virus Infections Medicine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CEL-SCI Corp
14.3.2 Fab'entech SA
14.3.3 Hemispherx Biopharma Inc
14.3.4 Kineta Inc
14.3.5 Nanotherapeutics Inc
14.3.6 Plex Pharmaceuticals Inc
14.3.7 Theravectys SA
